MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-12.49M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -92.37% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.23 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.23 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-2.75 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.62 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.93 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.40 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 5.10M |
| Free Float | 4.06M |
| Market Capitalization | $57.82M |
| Average Volume (Last 20 Days) | 8563.40 |
| Beta (Past 60 Months) | 0.49 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 2.87% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |